With lots of ASX shares to choose from on the Australian market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are outlined below. Here’s why they are bullish on them:

ANZ Group Holdings Ltd (ASX: ANZ)

According to a note out of Citi, its analysts have retained their buy rating and $39.25 price target on this banking giant’s shares. Citi highlights that Judo Capital Holdings Ltd (ASX: JDO) recently downgraded its earnings guidance due to three specific exposures. The broker believes these exposures are a credit risk problem and not signs of a systemic issue. As a result, it isn’t worried about ANZ at this stage. However, it concedes that the economy is in a challenging place and there are macro headwinds that the big banks could face. Nevertheless, the broker likes ANZ due to its exposure to business banking, which it prefers to retail banking at present. The ANZ share price is trading at $35.11 on Monday.

Neuren Pharmaceuticals Ltd (ASX: NEU)

A note out of Bell Potter reveals that its analysts have retained their buy rating on this biotechnology company’s shares with an improved price target of $23.50. This follows news that European regulators have reversed a negative recommendation on its Daybue product, which makes its approval quite likely now. Outside this, the broker estimates that the market is giving no value to Neuren’s NNZ-2591 product, which is under development. This could be a big mistake given how it estimates the product could be a multi-billion-dollar value asset if it succeeds in its Phase 3 trial. Trial results for NNZ-2591 are expected towards the end of 2027. The Neuren Pharmaceuticals share price is fetching $15.63 at the time of writing.

Qualitas Ltd (ASX: QAL)

Analysts at Macquarie have retained their outperform rating on this alternative asset manager’s shares with a trimmed price target of $3.95. According to the note, the broker was pleased to see Qualitas upgrade its margin guidance for long-term funds management EBITDA. It notes that this is being driven by benefits from an AI-enabled platform that should streamline the investment process. In addition, it has been pleased to see the company continues its long run of growing funds under management quicker than peers. It expects this to underpin strong earnings per share growth through to at least FY 2028. The Qualitas share price is trading at $3.01 this morning.

The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

More reading

• Why this ASX biotech stock is soaring 30% today
• Bell Potter says this ASX healthcare share could rise 93% (It’s not CSL)
• 5 things to watch on the ASX 200 on Monday
• Top brokers name 3 ASX shares to buy next week
• Here are the top 10 ASX 200 shares today

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group and Qualitas. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Some investors enjoy picking individual shares.

I do too. But I also think there is a lot to be said for owning an exchange-traded fund (ETF) that can quietly keep working in the background for years.

That is why I would consider buying Vanguard MSCI Index International Shares ETF (ASX: VGS).

It is not the most exciting ETF on the ASX. It does not try to pick the next hot sector, chase the latest theme, or concentrate money in a handful of fast-moving stocks.

But that is why I think it can be so useful.

A simple way to invest globally

The first thing I like about the VGS ETF is the access it provides.

The ETF gives investors exposure to a large portfolio of international shares across developed markets. That means an investor can gain exposure to many of the world’s largest companies without needing to pick individual winners overseas.

For Australian investors, I think that is valuable.

The ASX has plenty of good companies, but it does not offer the same depth in areas such as global technology, healthcare, consumer brands, industrials, payments, and software.

A global ETF can help fill that gap.

Rather than relying only on Australian banks, miners, retailers, and infrastructure names, investors can own a broader mix of businesses that earn money across many countries and industries.

That can make a portfolio feel more balanced over the long term.

Why simplicity can be powerful

One of the underrated strengths of ETFs is that they reduce the number of decisions an investor has to make.

Investing can become harder than it needs to be when every dollar has to be allocated to one specific company. Investors need to think about valuation, earnings, management, competition, risk, and whether something better is available.

With a broad ETF, the decision is simpler. Investors are buying a slice of a large market and letting time do more of the work.

That does not mean returns are guaranteed. Share markets can fall, currencies can move, and global investors can go through long periods of poor sentiment.

But I think the Vanguard MSCI Index International Shares ETF suits investors who want to keep adding money over time without constantly needing to make big calls.

It can be a useful default option for spare cash, regular investing plans, or long-term wealth building.

A long-term compounding machine

The reason I like VGS ETF is not because it will shoot the lights out every year.

It is because it offers exposure to thousands of businesses competing, adapting, reinvesting, and trying to become more profitable over time.

Some companies in the ETF will disappoint. Others may become much larger. The beauty of a broad ETF is that investors do not need to know in advance which names will do all the best work.

The fund can evolve as markets evolve.

That is important because the global economy changes. New leaders emerge, old leaders fade, and industries shift. A broad international ETF can move with those changes in a way that a static list of hand-picked shares may not.

Foolish Takeaway

If I wanted to keep investing simple, the Vanguard MSCI Index International Shares ETF would be one of the first ASX ETFs I would consider buying.

It offers global diversification, access to industries that are harder to find on the ASX, and a straightforward way to keep putting money to work over the long term.

It will still have weak years, and investors need patience. But for those trying to build wealth without overcomplicating the process, I think it could be a smart ETF to buy and hold for decades.

The post The amazing ASX ETF I’d buy for easy investing appeared first on The Motley Fool Australia.

More reading

• How to build a $100,000 ASX ETF portfolio
• Why US stocks have hit record highs while ASX shares have barely risen in 2026
• How to invest $500, $5,000, and $50,000 on the ASX
• The retirement ETF portfolio I’d add to super
• Own Vanguard ASX ETFs? Here is your next dividend

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Atlas Arteria Group (ASX: ALX) share price is in focus today following an update on the ongoing Dulles Greenway litigation, with the US District Court dismissing the 2024 rate case. Notably, recent legislative reforms have streamlined the regulatory process, offering more certainty for the company and its stakeholders.

What did Atlas Arteria report?

• The US District Court dismissed the Dulles Greenway 2024 rate case litigation against TRIP II.
• TRIP II is reviewing the decision and considering an appeal.
• Legislative reforms now allow for two-year toll applications and set defined timelines for regulatory decisions.
• The latest Dulles Greenway rate case, submitted in December 2025, continues as scheduled.

What else do investors need to know?

The dismissal relates directly to Atlas Arteria’s Dulles Greenway asset in the US, part of its portfolio spanning France, Germany, and the United States. Earlier this year, regulatory changes were enacted in Virginia that make toll application processes faster and more predictable, which could reduce costs and improve planning for the company.

Atlas Arteria remains active in engaging with the Commonwealth of Virginia, local governments, and communities to build and maintain positive partnerships. Its approach emphasises long-term stakeholder and shareholder value through constructive engagement and disciplined management.

What’s next for Atlas Arteria?

Atlas Arteria’s focus is now on evaluating legal options while working within the revised regulatory environment in Virginia. The latest toll rate application process is continuing, and management says it is progressing in line with schedules.

The company has reiterated its commitment to sustainable business practices and stakeholder value, signalling ongoing dialogue with authorities and communities across its global portfolio.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have remained flat, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Atlas Arteria reacts to Dulles Greenway litigation outcome appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• If you want to use this strategy to top up your superannuation you have to act today
• Here is the average Australian superannuation balance at ages 45, 55, and 65
• ASX 200 retail shares outperform on growing hopes interest rates have peaked
• DigiCo Infrastructure REIT CEO resigns

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.